PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
IOVA vs. CABA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between IOVA and CABA is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

IOVA vs. CABA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Iovance Biotherapeutics, Inc. (IOVA) and Cabaletta Bio, Inc. (CABA). The values are adjusted to include any dividend payments, if applicable.

-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-51.30%
-66.01%
IOVA
CABA

Key characteristics

Sharpe Ratio

IOVA:

-0.69

CABA:

-0.85

Sortino Ratio

IOVA:

-0.95

CABA:

-2.27

Omega Ratio

IOVA:

0.89

CABA:

0.74

Calmar Ratio

IOVA:

-0.54

CABA:

-0.98

Martin Ratio

IOVA:

-1.13

CABA:

-1.27

Ulcer Index

IOVA:

46.06%

CABA:

71.61%

Daily Std Dev

IOVA:

68.27%

CABA:

106.81%

Max Drawdown

IOVA:

-99.37%

CABA:

-96.63%

Current Drawdown

IOVA:

-96.36%

CABA:

-91.88%

Fundamentals

Market Cap

IOVA:

$1.76B

CABA:

$100.69M

EPS

IOVA:

-$1.48

CABA:

-$2.16

Total Revenue (TTM)

IOVA:

$90.38M

CABA:

$0.00

Gross Profit (TTM)

IOVA:

$1.27M

CABA:

-$819.00K

EBITDA (TTM)

IOVA:

-$287.93M

CABA:

-$90.11M

Returns By Period

In the year-to-date period, IOVA achieves a -21.89% return, which is significantly lower than CABA's -9.25% return.


IOVA

YTD

-21.89%

1M

-6.62%

6M

-51.31%

1Y

-63.35%

5Y*

-25.27%

10Y*

-4.67%

CABA

YTD

-9.25%

1M

-20.46%

6M

-66.01%

1Y

-90.80%

5Y*

-32.24%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

IOVA vs. CABA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IOVA
The Risk-Adjusted Performance Rank of IOVA is 1414
Overall Rank
The Sharpe Ratio Rank of IOVA is 1212
Sharpe Ratio Rank
The Sortino Ratio Rank of IOVA is 1111
Sortino Ratio Rank
The Omega Ratio Rank of IOVA is 1414
Omega Ratio Rank
The Calmar Ratio Rank of IOVA is 1515
Calmar Ratio Rank
The Martin Ratio Rank of IOVA is 1919
Martin Ratio Rank

CABA
The Risk-Adjusted Performance Rank of CABA is 55
Overall Rank
The Sharpe Ratio Rank of CABA is 77
Sharpe Ratio Rank
The Sortino Ratio Rank of CABA is 11
Sortino Ratio Rank
The Omega Ratio Rank of CABA is 33
Omega Ratio Rank
The Calmar Ratio Rank of CABA is 11
Calmar Ratio Rank
The Martin Ratio Rank of CABA is 1212
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

IOVA vs. CABA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Iovance Biotherapeutics, Inc. (IOVA) and Cabaletta Bio, Inc. (CABA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for IOVA, currently valued at -0.69, compared to the broader market-2.000.002.00-0.69-0.85
The chart of Sortino ratio for IOVA, currently valued at -0.95, compared to the broader market-4.00-2.000.002.004.006.00-0.95-2.27
The chart of Omega ratio for IOVA, currently valued at 0.89, compared to the broader market0.501.001.502.000.890.74
The chart of Calmar ratio for IOVA, currently valued at -0.58, compared to the broader market0.002.004.006.00-0.58-0.98
The chart of Martin ratio for IOVA, currently valued at -1.13, compared to the broader market-10.000.0010.0020.0030.00-1.13-1.27
IOVA
CABA

The current IOVA Sharpe Ratio is -0.69, which is comparable to the CABA Sharpe Ratio of -0.85. The chart below compares the historical Sharpe Ratios of IOVA and CABA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.001.502.002.50SeptemberOctoberNovemberDecember2025February
-0.69
-0.85
IOVA
CABA

Dividends

IOVA vs. CABA - Dividend Comparison

Neither IOVA nor CABA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

IOVA vs. CABA - Drawdown Comparison

The maximum IOVA drawdown since its inception was -99.37%, roughly equal to the maximum CABA drawdown of -96.63%. Use the drawdown chart below to compare losses from any high point for IOVA and CABA. For additional features, visit the drawdowns tool.


-90.00%-85.00%-80.00%SeptemberOctoberNovemberDecember2025February
-89.01%
-91.88%
IOVA
CABA

Volatility

IOVA vs. CABA - Volatility Comparison

The current volatility for Iovance Biotherapeutics, Inc. (IOVA) is 14.61%, while Cabaletta Bio, Inc. (CABA) has a volatility of 24.96%. This indicates that IOVA experiences smaller price fluctuations and is considered to be less risky than CABA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%60.00%SeptemberOctoberNovemberDecember2025February
14.61%
24.96%
IOVA
CABA

Financials

IOVA vs. CABA - Financials Comparison

This section allows you to compare key financial metrics between Iovance Biotherapeutics, Inc. and Cabaletta Bio, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab